{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-028610","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2026-06-15T11:02:38+00:00","discovered_at":"2026-06-15T11:05:00.335365+00:00","generated_at":"2026-06-15T11:05:17.044403+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Elite Pharmaceuticals reports positive bioequivalence for undisclosed anticonvulsant generic drug","bullets":["Pivotal BE study successful; generic product bioequivalent to branded anticonvulsant under fasting conditions.","IQVIA reports $840M combined branded and generic sales for the 12 months ending April 2026.","Elite to compile data and file ANDA with FDA; no specific timeline provided.","Study was open-label, randomized, single-dose crossover in healthy adult subjects."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-028610","json":"https://secwatch.observer/filing/0001493152-26-028610.json","markdown":"https://secwatch.observer/filing/0001493152-26-028610.md","text":"https://secwatch.observer/filing/0001493152-26-028610.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226028610/0001493152-26-028610-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226028610/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T11:05:17.044403+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}